Table A1.
Comparison of Expression of Progression/Resistance Factors in Imatinib-Responsive Versus Imatinib-Resistant Newly Diagnosed CML
| Gene | Median-Normalized Expression Levels |
ANOVA P | ANOVA P (adjusted) | t-test P | t-test P (adjusted) | |
|---|---|---|---|---|---|---|
| Optimal/Suboptimal | Resist | |||||
| PTGS1 | 0.378 | 0.931 | .001 | .024 | < .001 | .005 |
| LYN | 53.190 | 63.258 | .128 | 1.000 | .984 | 1.000 |
| PTPN22 | 14.450 | 9.120 | .135 | 1.000 | .047 | .932 |
| CEBPA | 1.592 | 0.993 | .161 | 1.000 | .063 | 1.000 |
| RUNX3 | 0.683 | 1.000 | .189 | 1.000 | .069 | 1.000 |
| FZD7 | 0.029 | 0.018 | .197 | 1.000 | .146 | 1.000 |
| CSF2 | 0.001 | 0.002 | .220 | 1.000 | .401 | 1.000 |
| STAT5A | 1.000 | 1.045 | .267 | 1.000 | .512 | 1.000 |
| BTK | 2.104 | 1.881 | .308 | 1.000 | .126 | 1.000 |
| RUNX1 | 3.546 | 3.955 | .339 | 1.000 | .176 | 1.000 |
| STAT5B | 2.532 | 2.995 | .352 | 1.000 | .720 | 1.000 |
| JAK2 | 2.734 | 2.843 | .439 | 1.000 | .205 | 1.000 |
| TEC | 0.588 | 0.561 | .486 | 1.000 | .243 | 1.000 |
| CD34 | 0.177 | 0.133 | .590 | 1.000 | .306 | 1.000 |
| ABL1 | 1.437 | 1.666 | .619 | 1.000 | .656 | 1.000 |
| ABCG2 | 0.007 | 0.014 | .711 | 1.000 | .449 | 1.000 |
| SLC22A1 | 0.175 | 0.197 | .851 | 1.000 | .579 | 1.000 |
| ABCC1 | 0.473 | 0.539 | .914 | 1.000 | .886 | 1.000 |
| STAT3 | 6.592 | 6.156 | .928 | 1.000 | .846 | 1.000 |
| SLC22A3 | 0.000 | 0.000 | .954 | 1.000 | .768 | 1.000 |
| ABCB1 | 0.045 | 0.072 | .955 | 1.000 | .776 | 1.000 |
Abbreviations: CML, chronic myelogenous leukemia; ANOVA, one-way analysis of variance; ANOVA P, P value of ANOVA test comparing three groups; ANOVA P adjusted, P value adjusted for multiple testing by Holm's method; t-test P, P value of t-test comparing resistant and response (suboptimal + optimal combined) groups; t-test P adjusted, P value of t-test adjusted for multiple testing by Holm's method.